Yuyu Pharma, Inc.

As of June 30, 2026, Yuyu Pharma, Inc. Pfd Registered Non-Voting/Issue 00 maintains a current ratio of 1.89, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.19, indicating elevated leverage, while an interest coverage ratio of 9.42 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Yuyu Pharma, Inc. Pfd Registered Non-Voting/Issue 00 posted a return on equity (ROE) of 9.86, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.42 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.11, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.57, useful for judging operating efficiency across full business cycles. The company generates approximately 576.91M in revenue per employee across its workforce of 250.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.02 indicates how many times Yuyu Pharma, Inc. Pfd Registered Non-Voting/Issue 00 sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Yuyu Pharma, Inc. Pfd Registered Non-Voting/Issue 00 recorded 695.22M in income tax expense. That works out to an effective tax rate of 5.30, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 13.13B, leaving 12.50B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Yuyu Pharma, Inc. Pfd Registered Non-Voting/Issue 00's stock has declined approximately 27.91% over the past 52 weeks. The 50-day moving average sits at 7,620.60, while the 200-day moving average is 9,528.00.

These figures cover the twelve months ended June 30, 2026. EBITDA reached 18.81B, while operating income came in at 13.16B.

As of June 30, 2026, Yuyu Pharma, Inc. Pfd Registered Non-Voting/Issue 00 holds 27.86B in cash and equivalents against 28.06B in total debt, resulting in a net debt position of 6.19B. Total book value stands at 132.20B, with working capital of 43.11B providing operational flexibility.

Yuyu Pharma, Inc. Pfd Registered Non-Voting/Issue 00 produced 21.05B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Yuyu Pharma, Inc. Pfd Registered Non-Voting/Issue 00 posted a gross margin of 38.83, reflecting its pricing power and cost economics. The operating margin of 9.12 and net profit margin of 8.66 provide insight into operational efficiency.

Yuyu Pharma, Inc. Pfd Registered Non-Voting/Issue 00's most recent stock split took place on March 30, 2021 with a 1:2 split ratio.